1
|
Thomas-Joulié A, Tran S, El Houari L, Seyve A, Bielle F, Birzu C, Lozano-Sanchez F, Mokhtari K, Giry M, Marie Y, Laigle-Donadey F, Dehais C, Houillier C, Psimaras D, Alentorn A, Laurenge A, Touat M, Sanson M, Hoang-Xuan K, Kas A, Rozenblum L, Habert MO, Nichelli L, Leclercq D, Galanaud D, Jacob J, Karachi C, Capelle L, Carpentier A, Mathon B, Belin L, Idbaih A. Prognosis of glioblastoma patients improves significantly over time interrogating historical controls. Eur J Cancer 2024; 202:114004. [PMID: 38493668 DOI: 10.1016/j.ejca.2024.114004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 03/01/2024] [Accepted: 03/01/2024] [Indexed: 03/19/2024]
Abstract
BACKGROUND Glioblastoma (GBM) is the most common devastating primary brain cancer in adults. In our clinical practice, median overall survival (mOS) of GBM patients seems increasing over time. METHODS To address this observation, we have retrospectively analyzed the prognosis of 722 newly diagnosed GBM patients, aged below 70, in good clinical conditions (i.e. Karnofsky Performance Status -KPS- above 70%) and treated in our department according to the standard of care (SOC) between 2005 and 2018. Patients were divided into two groups according to the year of diagnosis (group 1: from 2005 to 2012; group 2: from 2013 to 2018). RESULTS Characteristics of patients and tumors of both groups were very similar regarding confounding factors (age, KPS, MGMT promoter methylation status and treatments). Follow-up time was fixed at 24 months to ensure comparable survival times between both groups. Group 1 patients had a mOS of 19 months ([17.3-21.3]) while mOS of group 2 patients was not reached. The recent period of diagnosis was significantly associated with a longer mOS in univariate analysis (HR=0.64, 95% CI [0.51 - 0.81]), p < 0.001). Multivariate Cox analysis showed that the period of diagnosis remained significantly prognostic after adjustment on confounding factors (adjusted Hazard Ratio (aHR) 0.49, 95% CI [0.36-0.67], p < 0.001). CONCLUSION This increase of mOS over time in newly diagnosed GBM patients could be explained by better management of potentially associated non-neurological diseases, optimization of validated SOC, better management of treatments side effects, supportive care and participation in clinical trials.
Collapse
Affiliation(s)
- A Thomas-Joulié
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France; AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service d'Oncologie-Radiothérapie, F-75013 Paris, France
| | - S Tran
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, F-75013 Paris, France
| | - L El Houari
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Unité de Recherche Clinique, F-75013 Paris, France
| | - A Seyve
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - F Bielle
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, F-75013 Paris, France
| | - C Birzu
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - F Lozano-Sanchez
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - K Mokhtari
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, F-75013 Paris, France
| | - M Giry
- Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, F-75013 Paris, France
| | - Y Marie
- Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, F-75013 Paris, France
| | - F Laigle-Donadey
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - C Dehais
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - C Houillier
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - D Psimaras
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - A Alentorn
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - A Laurenge
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - M Touat
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - M Sanson
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - K Hoang-Xuan
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France
| | - A Kas
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Médecine Nucléaire, F-75013 Paris, France; Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, 75006 Paris, France
| | - L Rozenblum
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Médecine Nucléaire, F-75013 Paris, France; Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, 75006 Paris, France
| | - M-O Habert
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Médecine Nucléaire, F-75013 Paris, France; Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, 75006 Paris, France
| | - L Nichelli
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuroradiologie, F-75013 Paris, France
| | - D Leclercq
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuroradiologie, F-75013 Paris, France
| | - D Galanaud
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuroradiologie, F-75013 Paris, France
| | - J Jacob
- AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service d'Oncologie-Radiothérapie, F-75013 Paris, France
| | - C Karachi
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, F-75013 Paris, France
| | - L Capelle
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, F-75013 Paris, France
| | - A Carpentier
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, F-75013 Paris, France
| | - B Mathon
- Sorbonne Université, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, F-75013 Paris, France
| | - L Belin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Département de Santé Publique, Unité de Recherche Clinique Pitié-Salpêtrière-Charles Foix, Paris, France
| | - A Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie-Oncologie, F-75013 Paris, France; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Département de Santé Publique, Unité de Recherche Clinique Pitié-Salpêtrière-Charles Foix, Paris, France.
| |
Collapse
|
2
|
Kemoun G, Weiss E, El Houari L, Bonny V, Goury A, Caliez O, Picard B, Rudler M, Rhaiem R, Rebours V, Mayaux J, Bachet JB, Belin L, Demoule A, Decavèle M. Clinical features and outcomes of patients with pancreatic cancer requiring unplanned medical ICU admission: A retrospective multicenter study. Dig Liver Dis 2024; 56:514-521. [PMID: 37718226 DOI: 10.1016/j.dld.2023.08.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 07/27/2023] [Accepted: 08/17/2023] [Indexed: 09/19/2023]
Abstract
BACKGROUND We sought to describe the reasons for intensive care unit (ICU) admission and outcomes of patients with pancreatic cancer requiring unplanned medical ICU admission. PATIENTS AND METHODS Retrospective cohort study in five ICUs from 2009 to 2020. All patients with pancreatic cancer admitted to the ICU were included. Patients having undergone recent surgery were excluded (< 4 weeks). RESULTS 269 patients were included. Tumors were mainly adenocarcinoma (90%). Main reason for admission was sepsis/septic shock (32%) with a biliary tract infection in 44 (51%) patients. Second reason for admission was gastrointestinal bleeding (28%). ICU and 3-month mortality rates were 26% and 59% respectively. Performance status 3-4 (odds ratio OR 3.58), disease status (responsive/stable -ref-, newly diagnosed OR 3.25, progressive OR 5.99), mechanical ventilation (OR 8.03), vasopressors (OR 4.19), SAPS 2 (OR 1.69) and pH (OR 0.02) were independently associated with ICU mortality. Performance status 3-4 (Hazard ratio HR 1.96) and disease status (responsive/stable -ref-, newly diagnosed HR 2.67, progressive HR 4.14) were associated with 3-month mortality. CONCLUSION Reasons for ICU admissions of pancreatic cancer patients differ from those observed in other solid cancer. Short- and medium-term mortality are strongly influenced by performance status and disease status at ICU admission.
Collapse
Affiliation(s)
- G Kemoun
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive - Réanimation (Département R3S), Paris, France.
| | - E Weiss
- AP-HP Nord, Université de Paris, Hôpital Beaujon, Département d'anesthésie-réanimation, Clichy, France; Université de Paris, UMRS1149, Centre de recherche sur l'inflammation, Liver Intensive Care Group of Europe (LICAGE), France
| | - L El Houari
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, F-75013, Paris, France
| | - V Bonny
- AP-HP Sorbonne Université, site Saint-Antoine, Service de Médecine Intensive - Réanimation, Paris, France
| | - A Goury
- Unité de médecine intensive et réanimation polyvalente, Hôpital Robert Debré, CHU de Reims, France
| | - O Caliez
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service d'hépato-gastro-entérologie, Paris, France
| | - B Picard
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive - Réanimation (Département R3S), Paris, France
| | - M Rudler
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service d'hépato-gastro-entérologie, Paris, France; Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - R Rhaiem
- Service de chirurgie hépatobiliaire, pancréatique et oncologique digestive, Hôpital Robert Debré, CHU de Reims, France
| | - V Rebours
- AP-HP Nord, Université de Paris, Hôpital Beaujon, Service de Pancréatologie, Clichy, France; Université de Paris, INSERM, UMR 1149, pancreatic rare diseases (PaRaDis), centre de référence de maladies rares, Clichy, France
| | - J Mayaux
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive - Réanimation (Département R3S), Paris, France
| | - J B Bachet
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service d'hépato-gastro-entérologie, Paris, France
| | - L Belin
- Sorbonne-Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, F-75013, Paris, France
| | - A Demoule
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive - Réanimation (Département R3S), Paris, France; Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France
| | - M Decavèle
- AP-HP Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive - Réanimation (Département R3S), Paris, France; Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France
| |
Collapse
|
3
|
Birzu C, Boussier J, Belin L, Da Costa Pereira T, Quissac E, Zerara M, Lemaire N, Mokhtari K, Verreault M, Idbaih A. P10.17.B Androgen receptor signalling has independent prognostic value and is associated with resistance to temozolomide and tumour growth in glioblastoma. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The spectrum of sex differences in glioblastoma (GBM) is a rising topic. GBM is more frequent (sex ratio M:F=1.6) and seem to have worse prognosis in males (M) compared to females. Androgen receptor (AR) is expressed in GBM but its role in GBM biology and clinics is not yet fully understood.
Material and Methods
We have selected from our tumour tissue bank: (i) GBM samples with clinical, pathological and molecular annotations and (ii) GBM-patient derived cell lines -GBM-PDCL- with transcriptomic profiling and available tissue from parental tumours.AR expression was investigated using multiplex IHC Opal stained-FFPE sections. Sensitivity of PDCL to hormonotherapy (dihydrotestosterone or enzalutamide EZT) alone or combined with temozolomide (TMZ) was tested using WST1 viability assay. Response to drugs were correlated to AR expression (high: log2 [FPKM] >2 or low: log2 [FPKM] <2). PDCLs dihydrotestosterone secretion was examined by ELISA in both supernatants and cell lysates.
Results
In our cohort of 1188 IDH muted GBM patients, the median follow-up was 27.7 (25.8-31.3). The sex ratio M:F was 1.68 and the median age at diagnosis was 57 years [18-69]. Compared to males, females have better prognosis with a median overall survival of 26.1 months vs 20.8 months (p<0.0001). In multivariate analysis, male gender was an independent prognostic factor with a HR of 1.43 CI95%(1.21-1.69) (p<0.0001) adjusted on age, MGMT status and Karnofsky indice . Although interaction between age and sex was not significant (p = 0.854), HR of gender varied through age category 1.53 CI95%( 1.01-2.33 ), 1.51 CI95%( 0.888-2.55 ) and 1.38 CI95%( 0.857-2.21) for males <45 years, between 46-55 years and > 55 years respectively. In GBM tumours, AR staining was positive in 5- 30% tumour cells. After 72h exposure to 10nM dihydrotestosterone, ARhigh GBM-PDCLs exhibit AR nuclear translocation and c-myc expression upregulation, suggesting functional activation of the receptor. AR pharmacological blockade increased temozolomide sensitivity in ARhigh GBM-PDCLs regardless of the patient’s sex. Moreover, ARhigh PDCLs secreted DHT, suggesting autocrine and paracrine AR stimulation in tumour microenvironment.
Conclusion
Our study highlights the independent prognostic significance of sex in GBM patients, where males exhibit a worse prognosis. In GBM-PDCL, we show that androgen receptor is (i) functional in vitro and (ii) associated with resistance to temozolomide. Further studies are needed to investigate the role of AR in tumour tissue microenvironment.
Collapse
Affiliation(s)
- C Birzu
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, , Paris , France
- Service de Neurologie 2-Mazarin Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, , Paris , France
| | - J Boussier
- AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière – Charles Foix, Département de Santé Publique, , Paris , France
| | - L Belin
- INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière – Charles Foix, Département de Santé Publique, , Paris , France
| | - T Da Costa Pereira
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - E Quissac
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - M Zerara
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - N Lemaire
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - K Mokhtari
- Service de Neuropathologie Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - M Verreault
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| | - A Idbaih
- Institut du Cerveau, ICM, AP-HP, Inserm, UMR S 1127, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
- Service de Neurologie 2-Mazarin Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix , Paris , France
| |
Collapse
|
4
|
Kurtz J, Pujade-Lauraine E, Oaknin A, Belin L, Tsibulak I, Cibula D, Vergote I, Rosengarten O, Rodrigues M, de Gregorio N, Martinez-Garcia J, Pautier P, Mouret Reynier M, Selle F, D'Hondt V, Lobbedez FJ, Boissier EB, Floquet A, Heudel PE, Heitz F. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
5
|
Birzu C, Boussier J, Belin L, Lemaire N, Da Costa Pereira T, Mokhtari K, Verreault M, Idbaih A. 292P Androgen receptor signalling is associated with resistance to temozolomide and tumour growth in glioblastoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Simon-Tillaux N, Massol J, Hajage D, De rycke Y, Tubach F, Tohme J, Bouglé A, Belin L. Utilisation des essais ciblés émulés pour limiter les biais dans les études observationnelles: étude de l'effet du levosimendan dans le sevrage de l'ECMO-VA. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.03.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
7
|
Buffet C, Belin L, Attanasio R, Hegedüs L, Nagy EV, Papini E, Perros P, Leenhardt L. Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: a detailed view from the THESIS* questionnaire survey in France. Ann Endocrinol (Paris) 2021; 83:27-34. [PMID: 34861221 DOI: 10.1016/j.ando.2021.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Accepted: 11/15/2021] [Indexed: 10/19/2022]
Abstract
AIM To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. MATERIAL AND METHODS Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. RESULTS 534 of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. CONCLUSION The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.
Collapse
Affiliation(s)
- C Buffet
- Sorbonne Université, GRC n°16, GRC Thyroid Tumors, Thyroid Pathology and Endocrine Tumor Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
| | - L Belin
- Sorbonne Université, Biostatistics Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France
| | - R Attanasio
- Scientific Committee, Associazione Medici Endocrinologi, International Chapter of Clinical Endocrinology, Italy
| | - L Hegedüs
- Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
| | - E V Nagy
- Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - E Papini
- Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Albano, Rome, Italy
| | - P Perros
- Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
| | - L Leenhardt
- Sorbonne Université, GRC n°16, GRC Thyroid Tumors, Thyroid Pathology and Endocrine Tumor Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France
| |
Collapse
|
8
|
Biron C, Bernard V, Coste M, Belin L, Gouraud M, Sevin N, Raffi F, Lefèbvre M, Coutherut J, Scanvion A. « Optimisation du parcours PASS/CFPD » : évaluation du partenariat entre un centre fédératif prévention dépistage et une permanence d’accès aux soins de santé de 2012 à 2019. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Idbaih A, Canney M, Bouchoux G, Desseaux C, Vignot A, Lafon C, Chapelon J, Delattre J, Belin L, Carpentier A. P05.05 Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
The blood-brain barrier (BBB) limits penetration of drug therapies to the brain and may account for the limited effectiveness of chemotherapies in patients with primary brain cancer. An implantable ultrasound (US) device, SonoCloud, was developed to temporarily disrupt the BBB in patients with recurrent glioblastoma (rGBM) prior to carboplatin chemotherapy administration to enhance brain drug concentrations. BBB disruption was investigated with a single emitter device, SonoCloud-1 (SC1) and a three-emitter device, SonoCloud-3 (SC3) in a safety and feasibility study in rGBM patients at the Hôpitaux Universitaires La Pitié Salpêtrière in Paris, France (NCT02253212).
MATERIAL AND METHODS
The SC1 implant consisted of a 1 MHz, 10-mm diameter ultrasound transducer encapsulated in a biocompatible housing while the SC3 consisted of (3) separate SC1 emitters implanted in a triangular pattern to disrupt the BBB over a 3x larger volume. Patients were implanted with the SonoCloud device during tumor debulking or in a dedicated surgical procedure. The devices were activated monthly by connecting the device to an external generator via a transdermal needle. Intravenous injection of SonoVue® microbubbles was performed with device activation to temporarily disrupt the BBB. Magnetic resonance imaging (MRI) was performed after sonications with gadolinium contrast to verify BBB disruption followed by carboplatin infusion at AUC4-6. Patients received treatments until disease progression.
RESULTS
Between 2014 and 2016, 21 patients were registered for the study and implanted with the SC1; 19 patients received at least one sonication. Six additional patients were implanted and received sonications with the SC3. A total of 89 US sessions were performed to disrupt the BBB - 65 with the SC1 and 24 with the SC3. Treatment-related adverse events observed were transient and manageable. No carboplatin-related neurotoxicity was observed. SC1 patients with no or poor BBB disruption (n=8) visible on MRI had a median progression-free survival (PFS) of 2.73 months, and a median overall survival (OS) of 8.64 months. SC1 patients with clear BBB disruption (n=11) had a median PFS of 4.11 months, and a median OS of 12.94 months. The SC3 device was as well-tolerated as the SC1 device, with SC3 patients receiving between 1–12 monthly sonications.
CONCLUSION
These results provide the first safety data on the effects of disrupting the BBB in rGBM patients prior to carboplatin chemotherapy using an implantable low intensity pulsed ultrasound device on enlarged areas of brain. This study has now been completed. A new safety study with a larger device, SonoCloud-9, that covers the tumor and surrounding infiltrative regions, has started in France in early 2019 (NCT03744026). Work supported by CarThera and APHP.
Collapse
Affiliation(s)
- A Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | - M Canney
- CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - G Bouchoux
- CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - C Desseaux
- CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - A Vignot
- CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France
| | - C Lafon
- LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, Lyon, France
| | - J Chapelon
- LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, Lyon, France
| | - J Delattre
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | - L Belin
- Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, INSERM, CIC-1421, Paris, France
| | - A Carpentier
- Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires La Pitié-Salpêtrière, Service de Neurochirurgie and Sorbonne Université, UPMC Univ Paris 06, Paris, France
| |
Collapse
|
10
|
Belin L, Tan A, De Rycke Y, Dechartres A. Validation de la survie sans progression en tant que critère de substitution de la survie globale en oncologie : une revue systématique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Hajage D, Chauvet G, Belin L, Lafourcarde A, Tubach F, De rycke Y. Closed-Form variance estimator for weighted propensity score estimators with survival outcome. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
12
|
Belnou P, Dechartres A, Idbaih A, Tubach F, Belin L. Revue systématique des essais de phase I/II dans le glioblastome. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Chaigneau E, Russ G, Royer B, Bigorgne C, Bienvenu-Perrard M, Rouxel A, Leenhardt L, Belin L, Buffet C. TIRADS score is of limited clinical value for risk stratification of indeterminate cytological results. Eur J Endocrinol 2018; 179:13-20. [PMID: 29703794 DOI: 10.1530/eje-18-0078] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 04/27/2018] [Indexed: 02/05/2023]
Abstract
CONTEXT Thyroid nodules with cytological indeterminate results represent a daily and recurrent issue for patient management. OBJECTIVE The primary aim of our study was to determine if TIRADS (Thyroid Imaging Reporting and Data System) could be used to stratify the malignancy risk of these nodules and to help in their clinical management. Secondary objective was to estimate if this risk stratification would change after reclassification of encapsulated non-invasive follicular variant of papillary carcinomas (FVPTC) as non-invasive follicular thyroid neoplasm (NIFTP). PATIENTS AND METHODS Single-center retrospective study of a cohort of 602 patients who were referred for ultrasound-guided fine-needle aspiration from January 2010 to December 2016 with an indeterminate cytological result and in whom histological results after surgery were available. TIRADS score was prospectively determined for all patients included. Nodules that had been classified as FVPTC were submitted to a rereading of histological report and reclassified as NIFTP when judged relevant. A table of malignancy risk crossing Bethesda and TIRADS results was built before and after this reclassification. RESULTS The study included 602 cytologically indeterminate nodules. TIRADS score was positively correlated with the malignancy rate (P < 0.0001). Risk stratification with TIRADS was significant only in Bethesda V nodules (P = 0.0004). However, the risk of malignancy in this Bethesda V category was always above 45%, whatever the TIRADS score. CONCLUSION For a clinician facing an indeterminate cytological result for a thyroid nodule, return to TIRADS score is of limited value in most conditions to rule in or rule out malignancy and to guide subsequent management of patients.
Collapse
Affiliation(s)
- E Chaigneau
- Department of Endocrinology and Cardiovascular Prevention, Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
| | - G Russ
- Thyroid and Endocrine Tumors, Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
| | - B Royer
- Centre of Pathology and Radiology, Paris, France
| | - C Bigorgne
- Centre of Pathology and Radiology, Paris, France
| | | | - A Rouxel
- Centre of Pathology and Radiology, Paris, France
| | - L Leenhardt
- Thyroid and Endocrine Tumors, Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
| | - L Belin
- Department of Biostatistics, Public Health, and Medical Information, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
| | - C Buffet
- Thyroid and Endocrine Tumors, Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
| |
Collapse
|
14
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiother 2018; 22:222-228. [PMID: 29650388 DOI: 10.1016/j.canrad.2017.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 10/04/2017] [Indexed: 10/17/2022]
Abstract
PURPOSE To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. MATERIAL AND METHODS This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion. The study was designed to evaluate the toxicity at one year, 3 years and 5 years. RESULTS Sixty-four patients were included from October 2007 to August 2010. All of them received concurrent adjuvant radiotherapy and bevacizumab (in 24 cases after primary systemic treatment). All patients received non-fractionated radiotherapy to breast or chest wall with or without irradiation of regional lymph nodes. Early toxicity has been previously reported. Median follow-up was 46.4 months (range: 18-77 months). Median age was 53 years old (range: 23-68 years). The 3-years overall survival was 93% (range: 87-100%). Evaluation of the toxicity at 3 years was available for 67% of the patients. There was a low rate of toxicity: 14% grade 1 pain, 9% grade 1 fibrosis, 2% grade 1 telangiectasia, 2% grade 1 paresis, 7% grade 1 lymphedema and 2% grade 3 lymphedema. No grade 4 toxicity was observed. No patient had a left ventricular ejection fraction below 50% at 3 years. CONCLUSIONS Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.
Collapse
Affiliation(s)
- A Dautruche
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | - L Belin
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Cottu
- Oncology department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Bontemps
- Radiotherapy department, CHU Jean-Minjoz, 25030 Besançon, France
| | - C Lemanski
- Radiotherapy department, institut régional du cancer de Montpellier, 34298 Montpellier, France
| | - B de la Lande
- Radiotherapy department, institut Curie, René-Huguenin hospital, 92210 Saint-Cloud, France
| | - P Baumann
- Radiotherapy department, centre d'oncologie de Gentilly, 54000 Nancy, France
| | - F Missohou
- Radiotherapy department, centre Henri-Becquerel, 76038 Rouen, France
| | - C Lévy
- Radiotherapy department, centre François-Baclesse, 14000 Caen, France
| | - K Peignaux
- Radiotherapy department, centre Georges-François-Leclerc, 21079 Dijon, France
| | | | - F Denis
- Radiotherapy department, centre Jean-Bernard, 72000 Le Mans, France
| | - A Gobillion
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - V Pernin
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - Y Kirova
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
15
|
Goulard S, Coutance G, Belin L, Demondion P, Varnous S, Barthélémy O, Ouldamar S, Leprince P, Helft G. Risk factors for mid-term progression of cardiac allograft vasculopathy after heart transplantation only include donor characteristics in a large single center cohort. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Cosset JM, Belin L, Wakil G, Flam T, Thiounn N, Pierrat N, Pontvert D, Savignoni A, Chauveinc L. Second malignancies after permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. Cancer Radiother 2017; 21:210-215. [PMID: 28499661 DOI: 10.1016/j.canrad.2017.02.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2016] [Revised: 02/16/2017] [Accepted: 02/23/2017] [Indexed: 11/29/2022]
Abstract
PURPOSE To analyse the rate of secondary malignancies observed in a series of 675 prostate cancer patients who underwent a permanent implant brachytherapy between 1999 and 2003, and to compare the incidence with the expected rate in a matched general French population. MATERIAL AND METHODS The cohort included low-risk patients and a selection of "favourable-intermediate" risk patients. All patients were homogeneously treated using an intraoperative dynamic planning prostate brachytherapy technique, with loose 125-iodine seeds and a prescription dose of 145Gy. The mean follow-up was 132 months. RESULTS The 10-year overall survival for the entire cohort was 92% (95% confidence interval [CI]: 90-94). The 10-year relapse-free survival rate was 82% (95% CI: 79-85). Overall, 61 second cancers were registered. When comparing with a matched general French population, the standard incidence ratio (SIR) for bladder cancer was 1.02 (95% CI: 0.46-1.93). For colorectal cancer, the SIR was 0.45 (95% CI: 0.19-0.89). For lung cancer, the SIR was 0.38 (95% CI: 0.17-0.76). The SIR for all cancers was 0.61 (95% CI: 0.47-0.79). When excluding secondary colorectal and lung cancers (both with low SIRs in this series), the SIR for all cancers was 1.06 (95% CI: 0.77-1.29). CONCLUSION With a mean follow-up of more than 11 years, this series does not detect any excess risk of second cancers associated with permanent implant prostate brachytherapy. However, due to power limitation, a small increase in the risk of secondary malignancies cannot be totally ruled out.
Collapse
Affiliation(s)
- J-M Cosset
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Centre Charlebourg-La Défense, groupe Amethyst, 92250 La Garenne-Colombes, France.
| | - L Belin
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - G Wakil
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Charles Lemoyne hospital, 3120, boulevard Taschereau, Greenfield Park, J4V 2H1 Montréal, QC, Canada
| | - T Flam
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Fondation Saint-Jean-de-Dieu-Oudinot, 19, rue Oudinot, 75007 Paris, France
| | - N Thiounn
- Hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France
| | - N Pierrat
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - D Pontvert
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - A Savignoni
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - L Chauveinc
- Institut Curie, 26, rue d'Ulm, 75005 Paris, France; Centre de radiothérapie Hartmann, 4, rue Kléber, 93200 Levallois-Perret, France
| |
Collapse
|
17
|
Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. Ann Oncol 2017; 28:590-596. [DOI: 10.1093/annonc/mdw666] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard FC, Servois V, Comte A, Belin L, Sigal B, Bièche I. Abstract PD1-06: Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Genomic profile of breast cancer metastases (M) may differ from that of the primary tumor (PT). In a multicenter prospective study (ESOPE, NCT 01956552) including 130 patients with biopsies of the first metastatic deposit, we have shown that luminal breast cancers are the most prone to phenotypical subtype changes (Comte et al, ASCO 2016#550). We report here the first results of a comparative PT/M targeted next generation sequencing (NGS) mutational analysis.
Methods
Of 130 patients, 117 paired PT/M samples obtained before any treatment were available for analysis. Targeted Sequencing was done using Illumina Hiseq2500 technology with a custom made 95 breast cancer associated genes panel. Sequence data were aligned to the human reference genome (hg19) using Bowtie2 algorithm. Median depth was 607X and 87% of targets achieved 100X depth. SNVs and indels were called using GATK UnifiedGenotyper. We retained COSMIC confirmed non synonymous, exonic/splice variants and observed at a frequency lower than 0,1% in population. Further confirmation of detected variants was performed with comparison to public databases (cbioportal, tumorportal), and potential pathogenicity was evaluated with 4 different public algorithms. We present here the results obtained from the first 35 matched PT/M samples (liver mets 68%), focusing analysis on 40 genes including PIK3CA (20 genes), ER (6 genes) and MAPK (11 genes) pathways, RUNX1, CDH1 and TP53 genes.
Results
Patients characteristics are representative of patients with first line metastatic breast cancer (Comte et al, ASCO 2016#550). Among the 40 genes analyzed in the 70 samples, we detected 134 somatic mutations (70 in PT and 64 in M) including 15 indels and 119 SNV. Among these 134 mutations there were 74 different mutations (66SNV and 8 indels) classified pathogenic for 26 and of unknown pathogenicity for 48 of them. We detected at least 1 mutation in 31 PT and in 28 M. Median numbers of mutations were 1 in PT (range 1-9) and 1 in M (range1-22) samples (p=0.295, Wilcoxon rank sum test). Top ten mutated genes in PT included PIK3CA, TP53, NCOR1, NF1, GATA3, CDH1, ERBB3, PTEN, HRAS, INPP4B. In M samples, the 10 top genes were PIK3CA, TP53, ERBB3, AKT3, CDH1, ERBB4, GATA3, INPP4B, MET, MTOR. Only 3 ESR1 mutations were detected, including 1 PT/M pair and 1 M. Beyond highly shared PIK3CA and TP53 mutations, overall crude PT/M discordance rate was 31%. Analysis by histological subtypes showed PT and M specific mutational profiles, suggesting a role in ERB gene family (notably ERBB3) and MAPK driven pathways in early metastatic progression. Specific metastatic site analysis suggested enrichment in MAPK pathway mutations in liver metastases when compared to other sites. Variant allelic fractions were globally not significantly different between PT and M samples.
Conclusion
In this prospective multicenter series of systematic biopsies of first metastases, we report a targeted mutational analysis of matched PT and M samples not modified by previous therapy exposure. Early analyses suggest specific genotypical changes according to tumor subtype and/or metastatic site. Extended and updated results will be reported at the meeting.
Citation Format: Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard F-C, Servois V, Comte A, Belin L, Sigal B, Bièche I. Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-06.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Boulai
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Baulande
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - P Legoix-Ne
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Bernard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Benhamo
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - EGC Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - W Chemlali
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Campone
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - TD Bachelot
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Giacchetti
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - J Bonneterre
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - B Sigal
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
19
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Abstract P1-10-17: Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-10-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives
The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT).
Materials/Methods
Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during RT, 12 months and 36 months after its completion.
Results
Sixty-four patients were included from october 2007 to august 2010. They all received adjuvant RT and BV concomitant treatment, plus neo-adjuvant BV for 24 patients. RT was adjuvant and normo-fractionated. Twelve months toxicity was available for 60 patients and 36 months toxicity was available for 43 patients. Median follow-up was 46 months (18-77). Median age was 51 years old (23-68). Among 63 evaluated patients during RT, acute radiation dermatitis was observed in 48 (76%) patients : Grade 1 for 27 (43%), grade 2 for 17 (27%), grade 3 for 4 patients (6%). Grade 2 acute oesophagitis was observed in 1 patient. At 3 years, few toxicities were observed : 6 patients (14%) had grade 1 pain, 4 (9%) had grade 1 fibrosis, one (2%) had grade 1 telangiectasis, one (2%) had grade 1 paresis, 3 (7%) had grade 1 lymphoedema and one grade 3 lymphoedema. No grade 4 toxicity was observed. At 12 months, only one evaluated patient had a LVEF <50% and none at 36 months.
Conclusions
Concurrent bevacizumab with locoregional RT is associated with acceptable early and late 3-years toxicities in patients with BC. Determination of late toxicity at 60 months is currently underway.
Citation Format: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-17.
Collapse
Affiliation(s)
- A Dautruche
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - L Belin
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Cottu
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Bontemps
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Lemanski
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - B De La Lande
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Baumann
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Missohou
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Levy
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - K Peignaux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Reynaud-Bougnoux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Denis
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Gobillion
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - N Ady Vago
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Fourquet
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - Y Kirova
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| |
Collapse
|
20
|
Le Ray E, Belin L, Plancher C, Bouscary D, Kirova Y. Intensity Modulated Radiation Therapy by Tomotherapy (IMRT) Concurrent With a Short Systemic Treatment for Solitary Plasmacytoma of the Bone (SPB) With Improvement of Progression-Free Survival. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Cosset JM, Flam T, Belin L, Thiounn N, Pierrat N, Pontvert D, Wakil G, Savignoni A, Chauveinc L. Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003. Cancer Radiother 2016; 20:261-7. [DOI: 10.1016/j.canrad.2016.02.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2015] [Revised: 02/01/2016] [Accepted: 02/05/2016] [Indexed: 10/21/2022]
|
22
|
Belin L, De Rycke Y, Broët P. Comparaison de deux designs de phase II utilisant un critère de jugement censuré dans le cadre d’un suivi réduit. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
23
|
Asselain B, Sevellec M, Le Bideau S, Cotasson-Guillet F, Belin L, Lhuillier D, Rérolle E, Le Peltier N, Bourillon M. Travailler après un cancer : bilan 6ans après la reprise. Analyse d’une cohorte de 153 salariés. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.03.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
24
|
Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard FC, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Abstract P2-05-06: Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Cumulative evidence for phenotypic and molecular heterogeneity between primary breast cancer (BC) site and matched metastasis (mets) has been obtained in retrospective studies. Current expert consensus suggests performing biopsies of mets, but clinical utility and cost are unknown. The primary objective of the ESOPE study (NCT01956552) was to compare the phenotype and genotype of the primary tumor (PT) with those of matched mets at time of first distant relapse, before the start of any treatment, in order to optimize the treatment of mets
PATIENTS and METHODS: Between Nov. 2010 and Sept. 2013, we conducted a prospective multicenter study on BC patients (pts) with diagnosis of first mets. All pts were to have available Formalin-Fixed Paraffin-Embedded (FFPE) PT sample and mets accessible to either percutaneous or surgical sampling. All tissue samples were centrally analyzed with immunohistochemistry (ER, PgR, HER2, and Ki67) and FISH when indicated. Frozen samples were stored for further analyses. We recorded intended therapeutic decision before and after biopsy.
RESULTS: Of 93 pts included, 89 were eligible for biopsy. Median age was 57 years (28-81); median interval between PT and mets was 42 months (0-211), including 14 pts with novo metastatic breast cancer. Mets biopsy was performed in 85 pts (96%, refusal n=2, not feasible n=2). Toxicity was limited to only 1 grade 1 hemorrhage. Sampled sites were liver (44%), lung (16%), bone (13%), lymph node (13%), skin/muscle/chest wall (9%), ovary/peritoneum (4%), and adrenal gland (1%). PT was not available in 4 pts; mets biopsy was non contributive in 6 pts but led to a diagnosis of second primary cancer in 3 pts.
In 72 pts with matched PT and mets, PT were luminal A (n=11), luminal B (n=33), triple negative (n=13), HER2 (n=13), non-evaluable (n=2). Mets were luminal A (n=6), luminal B (n=30), triple negative (n=16), HER2 (n=14), non-evaluable (n=6). Discrepancy rates were: ER 18% [kappa for concordance =0.6, CI 95 % (0.42-0.77)], PgR: 39% [kappa=0.19, CI 95% (0.01-0.39)], Her2: 4% [kappa=0.86, CI 95% (0.7-1)], Ki67: 25% [kappa=0.19, CI 95% (-0.09; 0.49)].
The most frequent discrepancy rate was observed in pts with lum A PT, as only 3/10 developed Lum A mets. HER2 and triple negative were the most stable subtypes (12/13 and 12/12 respectively). Most importantly, mets biopsy led to a change in therapeutic decision in 25 pts (independent evaluation by 2 oncologists). Additional comparative targeted NGS analyses are ongoing on a first subset of 54 FFPE paired samples, and parallel whole exome sequencing is planned on 38 paired samples with available constitutional DNA.
CONCLUSION: Comparative analysis of breast cancer PT and first mets is routinely feasible, with very low morbidity and a significant impact for patients' management: 29% had a second cancer diagnosis or were proposed a therapeutic change. Furthermore, this study will provide additional data on quality and quantity of tissue available for molecular analysis, and ultimately in terms of cost-efficacy.
Citation Format: Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard F-C, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-06.
Collapse
Affiliation(s)
- A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - B Sigal-Zafrani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Diéras
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - O Mariani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - D Szwarc
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | | | - ECG Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| |
Collapse
|
25
|
Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Bollet M, Vago NA, Dendale R, Campana F, Fourquet A, Kirova YM. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. Br J Radiol 2015; 88:20140800. [PMID: 25645108 DOI: 10.1259/bjr.20140800] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC). METHODS Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT. RESULTS From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1-2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%). CONCLUSION The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC. ADVANCES IN KNOWLEDGE The largest series of this association.
Collapse
Affiliation(s)
- V Pernin
- 1 Radiotherapy Department, Institut Curie, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Sevellec M, Belin L, Le Bidault S, Stakowski H, Cotasson F, Bourrillon MF, Le Peltier N, Asselain B. Reprise du travail après cancer du sein. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2014.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
27
|
Pernin VE, Belin L, Gobillion A, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Bougnoux P, Peignaux K, Denis F, Kirova Y. Abstract P5-14-11: Locoregional toxicities after adjuvant radiotherapy with or without concurrent bevacizumab in patients with non-metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-14-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives
Few data are available regarding the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (RT) in breast cancer, especially in terms of late toxicity. The aim of this study was to determine early and late loco-regional toxicities among patients with non-metastatic breast cancer treated with this combination.
Materials/Methods
In our prospective and descriptive study, we analyzed loco-regional toxicities of adjuvant RT in patients with non-metastatic breast cancer receiving either concurrent bevacizumab or not in the randomized trial BEATRICE. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events (v3.0). Evaluation was done during RT and 12 months after the end of RT. All patients provided written informed consent before enrollment. Statistical analysis was performed to analyze toxicity between the two groups.
Results
From September 2007 to July 2009, we included 84 patients from the randomized trial BEATRICE which evaluate the efficacy and safety of the addition of bevacizumab to standard adjuvant therapy in patients with triple negative breast cancer; 39 women received an adjuvant RT with concurrent bevacizumab and 45 women received an adjuvant RT alone. Evaluation at 12 months was available for all the patients. All patients had a triple negative non-metastatic breast cancer and had an adjuvant chemotherapy then RT. Among patients receiving concurrent bevacizumab with RT, a total of 35 patients (90%) achieved a whole breast irradiation (median dose: 50 Gy) with a boost in the surgical bed (median dose: 16 Gy) and 4 patients (10%) had a post mastectomy RT (median dose 50 Gy); lymph node RT was performed in 19 patients (49%) with internal mammary chain RT in 12 patients (31%). Mean time of bevacizumab treatment was 11.7 months [2.1-12.6] and mean total dose of bevacizumab was 15000 mg [3330-28080]. Among patients receiving RT alone, 38 patients (84%) achieved a whole breast irradiation (median dose: 50 Gy) with a boost in the surgical bed (median dose: 16 Gy) and 7 patients (16%) had a post mastectomy RT (median dose 50 Gy); lymph node RT was performed in 21 patients (47%) with internal mammary chain RT in 14 patients (31%). Radiation treatment parameters were not significantly different between the two groups. Incidence of acute grade 3 dermatitis was 10% in patients receiving bevacizumab associated with RT and 6% in patients receiving RT alone without significant difference. One year after the end of RT, the most common late toxicities in the group receiving bevacizumab and RT were grade 1-2 pain (18%), grade 1-2 fibrosis (8%), grade 1-2 arm lymphedema (8%) and grade 1-2 telangiectasia (6%).There was no significant difference in pain, radiation fibrosis, telangiectasia, arm lymphedema and dyspnea between the two groups. No patient experienced grade 3-4 toxicity in the two groups.
Conclusions
Our results indicate that concurrent bevacizumab with loco-regional RT provide acceptable early and late toxicities after one year in patients with non-metastatic breast cancer.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-14-11.
Collapse
Affiliation(s)
- V-E Pernin
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - L Belin
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - A Gobillion
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - P Cottu
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - P Bontemps
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - C Lemanski
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - B De La Lande
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - P Baumann
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - F Missohou
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - C Levy
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - P Bougnoux
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - K Peignaux
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - F Denis
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| | - Y Kirova
- Institut Curie, Hospital, Paris, France; Institut Curie, Hospital, Clinical Research, Paris, France; CHU Jean Minjoz, Besançon, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Institut Curie, Hospital, Saint Cloud, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; CHRU de Tours, Tours, France; Centre Georges-François Leclerc, Dijon, France; Clinique Jean Bernard, Le Mans, France
| |
Collapse
|
28
|
Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Kirova Y. Early and Late Toxicity of Adjuvant Radiation Therapy Associated With Concurrent Bevacizumab in Patients With Breast Cancer. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.621] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Jacob J, Belin L, Pierga J, Gobillion A, Dendale R, Beuzeboc P, Campana F, Fourquet A, Kirova Y. Étude prospective monocentrique de l’association du trastuzumab à la radiothérapie locorégionale mammaire. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, Campana F, Bollet MA, Fourquet A, Kirova Y. Étude prospective monocentrique de la toxicité et de l’efficacité du trastuzumab concomitant à la radiothérapie. Cancer Radiother 2013; 17:183-90. [DOI: 10.1016/j.canrad.2012.12.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2012] [Revised: 12/14/2012] [Accepted: 12/26/2012] [Indexed: 10/27/2022]
|
31
|
Jacob J, Belin L, Pierga JY, Vincent-Salomon A, Dendale R, Beuzeboc P, Cottu PH, Campana F, Fourquet A, Kirova YM. Abstract P5-21-03: Concurrent loco-regional radiotherapy and trastuzumab in early-stage breast cancer: Long term results of prospective single-institution study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-21-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To evaluate the early and late heart and skin toxicities, as well as the efficacy of concurrent adjuvant trastuzumab-radiotherapy (RT) for breast cancer (BC), with group with internal mammary chain (IMC) RT.
Material and methods: Prospective study of 308 patients (pts) treated between 2000 and 2009 by concurrent trastuzumab with normofractionated RT for non-metastatic BC. Left ventricular ejection fraction (LVEF) was assessed by echocardiography or myocardial scintigraphy at baseline, before and after RT, every three months for one year, then annually. A LVEF strictly lower than 55%, was considered as altered. Trastuzumab was delivered every three weeks (8 mg/kg in the first infusion then 6 mg/kg) during a median time of 12 months (3–62). All toxicities were evaluated using the Common Terminology Criteria for Adverse Effects version 3.0. Survival data were defined as the time from the histological diagnosis of BC until occurrence of the event. Loco-regional recurrence free- and alive pts were censored at the date of their last known contact. Survival and interval rates as well as their confidence interval (CI) were calculated using the Kaplan–Meier method.
Results: Median age was 52 years (25–83). Median follow-up was 50 months (13–126). The clinical tumour staging was: T0 or T1 in 131 pts (43.4%), T2 in 122 pts (40.4%), T3 or T4 in 49 pts (16.2%). The regional lymph nodes were histologically involved in 132 pts (43.0%). The left breast was treated in 155 pts (50.3%). The IMC was irradiated in 227 pts (73.7%), among them 114 (37.0%) in the left side. Before trastuzumab, anthracycline-based regimens were administered in 280 pts (90.9%). The median dose of trastuzumab was 6145 mg (1845–29180). Acute skin toxicity was acceptable with 226 (74.1%) grade 1, 67 (22.0%) grade 2 and 12 (3.9%) grade 3 skin reactions. Esophagitis was observed in 31 pts (10.0%): 26 (8.4%) grade 1; 4 (1.3%) grade 2, and 1 (0.3%) grade 3. Out of 286 pts with assessments at the median time of 23 months, late telangiectasia grade 1 occurred in 14 pts (4.9%) and grade 2 in 10 pts (3.5%), local pain grade 1 in 39 pts (13.7%) and grade 2 in 8 pts (2.8%), fibrosis grade 1 in 53 pts (18.6%) and grade 2 in 20 pts (7.0%). At the completion of RT, 11 pts (3.6%), whose cardiologic assessment at baseline was normal, presented a clinically silent LVEF alteration. During follow-up, 44 patients experienced cardio-vascular morbidity revealed by: asymptomatic LVEF alteration (50.0%), thrombo-embolic event (18.2%), tachycardia (15.9%), ischemic cardiomyopathy (6.8%), pericarditis (4.5%), hypertrophic cardiomyopathy (2.3%) or arterial hypertension (2.3%). The cumulative incidence of these events at 48 months was 13.3% CI95% [9.4; 17.2]. A symptomatic congestive heart failure was reported for 3 pts (1.0%). No death of cardiac origin was observed. At 48 months, loco-regional control was 95% CI95% [92; 98] and overall survival was 98% CI95% [96; 100].
Conclusions: In this prospective study of BC pts treated with trastuzumab and RT, both the rates of skin and esophageal toxicities were acceptable with excellent local control. Further follow-up is warranted to assess late cardiac toxicity.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-21-03.
Collapse
Affiliation(s)
- J Jacob
- Institut Curie, Paris, France
| | - L Belin
- Institut Curie, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, Campana F, Bollet M, Fourquet A, Kirova Y. Cardiotoxicité de l’association trastuzumab–radiothérapie mammaire : une étude prospective monocentrique. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Asselain D, Belin L, Le bideau S, Stakowski H, Asselain B, Bourrillon MF. Difficultés rencontrées lors de la reprise du travail après un cancer du sein. ARCH MAL PROF ENVIRO 2012. [DOI: 10.1016/j.admp.2012.03.668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Jacob J, Belin L, Daveau-Bergerault C, Gobillion A, Dendale R, Beuzeboc P, Campana F, Bollet M, Fourquet A, Kirova Y. 463 Concurrent Radiotherapy and Trastuzumab in Early-stage Breast Cancer – A Prospective Single Institutional Experience. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70528-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F, Campana F, Fourquet A, Bollet MA. [Breast conserving surgery in locoregional treatment of breast carcinoma after Hodgkin lymphoma]. Cancer Radiother 2012; 16:128-35. [PMID: 22341508 DOI: 10.1016/j.canrad.2011.10.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Revised: 09/09/2011] [Accepted: 10/12/2011] [Indexed: 11/27/2022]
Abstract
PURPOSE To report characteristics and outcome of breast cancer after irradiation for Hodgkin lymphoma with special focus on breast conservation surgery. PATIENTS AND METHODS Medical records of 72 women who developed either ductal carcinoma in situ or stage I-III invasive carcinoma of the breast after Hodgkin lymphoma between 1978 and 2009 were retrospectively reviewed. RESULTS Median age at Hodgkin lymphoma diagnosis was 23 years old. Median total dose received by the mediastinum was 40 Gy, mostly by a mantle field technique. Breast cancer occurred after a median time interval of 21 years. Ductal invasive carcinoma and ductal carcinoma in situ represented respectively 71% and 19% of the cases. Locoregional treatment for breast cancer consisted of mastectomy with or without radiotherapy in 39 patients and of lumpectomy with or without adjuvant radiotherapy in 32 patients. The isocentric lateral decubitus radiation technique was used in 17 patients after breast conserving surgery (57%). With a median follow-up of 7 years, 5-year overall survival rate and locoregional control rate were respectively 74.5% and 82% for invasive carcinoma and 100% and 92% for in situ carcinoma. Thirteen patients died of progressive breast cancer and contralateral breast cancer was diagnosed in ten patients (14%). CONCLUSIONS Breast conserving treatment can be an option for breast cancers that occur after Hodgkin lymphoma despite prior thoracic irradiation. It should consist of lumpectomy and adjuvant breast radiotherapy with use of adequate techniques, such as the lateral decubitus isocentric position.
Collapse
Affiliation(s)
- S Haberer
- Département de radiothérapie, institut Curie, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Asselain D, Belin L, Le Bihan S, Stakowski H, Asselain B, Bourillon M. Difficultés rencontrées lors de la reprise du travail après un cancer du sein. ARCH MAL PROF ENVIRO 2011. [DOI: 10.1016/j.admp.2011.10.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
37
|
Berges O, Belin L, Zefkili S, Bolle S, Benamor M, Petras S, Jouffroy T, Savignoni A, Rodriguez J, Giraud P. Parotid-sparing Tomotherapy for Head and Neck Cancers: Preserved Parotid Function after Tomotherapy on Quantitative Salivary Scintigraphy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Berges O, Belin L, Zefkili S, Bolle S, Benamor M, Petras S, Jouffroy T, Savignoni A, Rodriguez J, Giraud P. La tomothérapie hélicoïdale des cancers ORL : évaluation scintigraphique prospective de la préservation des glandes parotides. Cancer Radiother 2010. [DOI: 10.1016/j.canrad.2010.07.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Belin L, Bourrillon MF, Stakowski H, Le Bideau S, Sevellec M, Asselain B. Répercussions des cancers sur la vie professionnelle : étude réalisée auprès de 402 salariés en Île-de-France. Rev Epidemiol Sante Publique 2010. [DOI: 10.1016/j.respe.2010.06.079] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
40
|
Bollet MA, Belin L, Dieras V, Thibault F, Reyal F, Campana F, Kirova YM, Pierga J, Sigal-Zafrani B, Fourquet A. Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Lillienberg L, Baur X, Doekes G, Belin L, Raulf-Heimsoth M, Sander I, Ståhl A, Thissen J, Heederik D. Comparison of four methods to assess fungal alpha-amylase in flour dust. Ann Occup Hyg 2000; 44:427-33. [PMID: 10963707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The aim of the study was to compare four different immunological methods to analyse fungal alpha-amylase in flour dust samples. Three European research groups have independently developed four immuno assay based methods to measure alpha-amylase in air samples. Three of the methods use polyclonal antibodies and one method uses monoclonal antibodies. Eighty personal samples have been collected during two to three work-shifts in four bakeries. Sampling was performed with PAS-6 inhalable dust samplers and aliquots from each sample were analysed by the three laboratories. The agreement between the four methods was high compared with agreement between immunological methods to measure other allergens in the air, e.g. for rat allergens. For the three methods with polyclonal antibodies the mean differences for individual samples was less than a factor of two. The arithmetic means (AM) of the estimated alpha-amylase exposure were 12.5, 11.3, 8.6 and 25.9ng/m(3) for the respective methods with values ranging from below the detection limit to 192, 215, 207 and 615 ng/m(3). The AM for all samples analysed by the methods with polyclonal antibodies varied by about a factor of 1.5. About one-third of the values were below or at the detection limit for all methods. In a regression analysis the squared correlation coefficients (R(2)) between the methods varied between 0.91 and 0.95 for the log transformed values. For workplace monitoring, results from the methods using polyclonal antibodies will be relatively comparable. High levels of alpha-amylase might differ in absolute numbers with a factor of two or more between the different methods but will anyway be considered as high and should result in preventive actions. On the other hand, this study also shows that despite the relative agreement between methods, there is a clear need for standardization.
Collapse
Affiliation(s)
- L Lillienberg
- Department of Occupational Medicine, Sahlgrenska University Hospital, Göteborg, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Olaison L, Belin L, Hogevik H, Alestig K. Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med 1999; 159:607-15. [PMID: 10090118 DOI: 10.1001/archinte.159.6.607] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND Long-term parenteral beta-lactam treatment is often complicated by adverse reactions that necessitate drug withdrawal. OBJECTIVE To evaluate the incidence and mechanism of beta-lactam adverse reactions during an 8-year period in all episodes of suspected infective endocarditis in patients treated at a university-affiliated institution. METHODS Patients with 215 consecutive episodes of beta-lactam treatment for 10 days or more were prospectively enrolled during 2 periods, January 1984 through December 1988 and January 1993 through December 1995, and compared with 51 episodes of vancomycin hydrochloride treatment for 10 days or more. Incidents of adverse reactions, such as fever, rash, or neutropenia, were registered. Neutrophil counts, eosinophil counts, and penicillin antibodies were studied. Patients with delayed adverse reactions to penicillin G sodium were rechallenged with penicillin v potassium. RESULTS Incidence of delayed adverse reactions during treatment was 33% with beta-lactams compared with 4% with vancomycin. Rates of adverse event for beta-lactams increased continuously from treatment day 15 to day 30. A 6-fold difference in capacity to induce adverse events was found with different beta-lactams. Penicillin G induced neutropenia in 14% and any adverse event in 51% of treated episodes. Mean daily doses significantly influenced the frequency of adverse events. Occurrence of hemagglutinating penicillin antibodies was significantly related to patients whose penicillin-treated episodes were complicated with adverse events. Patients with delayed adverse reactions to penicillin G were safely rechallenged with penicillin. CONCLUSIONS Incidence of delayed adverse reactions to beta-lactams increases sharply when parenteral treatment is extended beyond 2 weeks. Penicillin G is the most frequent inducer of adverse reactions among beta-lactams studied. An immunological reaction mediated by antibodies to the penicilloyl determinant may be involved in the pathogenesis, possibly enhanced by a dose-related toxic trigger mechanism. Beta-Lactam-induced neutropenia followed a uniform pattern, occurring after, on average, 21 days of treatment, and might be due to both immunologic and toxic effects of treatment. Patients with a late adverse reaction to penicillin can safely be re-treated with penicillin, although they should remain under close surveillance if treatment extends beyond 2 weeks.
Collapse
Affiliation(s)
- L Olaison
- Department of Infectious Diseases, Institute of Internal Medicine, Göteborg University, Sahlgrenska University Hospital, Sweden.
| | | | | | | |
Collapse
|
43
|
Abstract
The prevalence of asthma among schoolchildren in Costa Rica is very high -- at the level of 20-30% -- and the reason is still unknown. A group of children from our previous epidemiologic study was randomly selected in order to establish the relation between asthma symptoms and allergy sensitization to common allergens. Serum samples from children with and without asthma were analyzed for the presence of IgE antibodies to 36 different allergens, for the presence of IgE antibodies to a pool of 10 common allergens, and for total serum IgE. The most prevalent IgE antibodies were those to mite, cockroach, dog, and house-dust allergens with MAST pipettes for the serologic measurements. Positive reactions to house dust, mite, cat, and the two molds (Alternaria and Cladosporium), and food allergens such as egg white, peanut, and shellfish were significantly more prevalent among the asthmatics than the nonasthmatics. Sensitization was equally prevalent at different ages, but the house-dust, mite, cat, dog, cockroach, Alternaria, and egg-white allergens had sensitized boys more often than girls (P < 0.01). The result of the analysis of IgE antibodies to a pool of 10 common allergens by Phadiatop supported the MAST pipette results, showing allergen sensitization in 57.7% of the asthmatic children and 42.3% in the nonasthmatic group. The concentration of IgE was significantly higher among the asthmatic children (372.2 kU/l) than among the nonasthmatic children (249.1 kU/l) (P < 0.00001). Parasitic infestations were not examined in this study, but in most of Costa Rica these have largely been eliminated and could not explain the high total IgE levels. Our data indicate that the very high prevalence of bronchial asthma in Costa Rican schoolchildren can be related to sensitization, especially to airborne indoor allergens such as those of mites, cockroaches, and dogs.
Collapse
Affiliation(s)
- M Soto-Quiros
- Department of Pediatrics, Hospital Nacional de Niños, University of Costa Rica, San Jose
| | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Previous studies of schoolchildren in Costa Rica have shown an asthma prevalence of 23% and a high level of sensitization, particularly to mite allergens. As a continuation of these studies, some 400 dust samples were collected from various places in Costa Rica, and parts of these were analyzed for specific mite and cockroach allergens, as well as for the number of mites and amount of guanine. Guanine was quantified by a diazo, as well as an HPLC method, which were found to be highly correlated. The concentrations of guanine by the diazo method, Der p 1, Der f 1, and the number of mites were higher in bed dust than in bedroom floor dust, and it was possible to quantify mite allergens and guanine in almost all bed-dust samples. The mean levels were 2-3 times higher than the proposed risk level for elicitation of symptoms in mite-sensitive asthmatics. Bed and bedroom floor dust contained more guanine and mite allergen in humid (> 2000 mm rain) than in drier places (P < 0.05), but the number of mites in bed and bedroom floor dust was higher in less humid places (P = 0.01). The guanine content in bedroom floor dust was higher in areas with a temperate climate than in areas with a warmer climate (P < 0.001, Bartlett's chi square [BCS]), as was the number of mites (P < 0.01, Kruskal-Wallis [KW], 0.04, BCS) and the Der p 1 concentration (P = 0.01, BCS; P = 0.02, KW). The Der f 1 concentration in bedroom floor dust was higher in a warmer than in a temperate climate (P < 0.001, BCS). More guanine and mites were found in urban than in rural bed dust (P = 0.03, KW). Dust samples from the metropolitan area (temperate climate) of Costa Rica contained higher levels of guanine (P < 0.01) and Der p 1 (P = 0.07) than the coastal areas, but very little Der f 1. In these samples, guanine and Der p 1 allergen were closely related, and 2 micrograms of the allergen was equivalent to 0.49 mg of guanine. Two-thirds of bed and floor samples collected on cotton filters contained Bla g 2 allergen at mean levels of 1.6 and 2.1 units/g dust, respectively. Cockroach allergen was, however, absent in all bed samples from the metropolitan area, but did occur in very high concentrations in the coastal bed dust samples collected with tighter polyester filters. In conclusion, the concentration of guanine and Der p 1 was very high in the bed dust of Costa Rican homes. Some factors, such as humidity, small houses for large families, and type of bedding, probably favored the heavy mite infestation, which is probably related to the widespread occurrence of bronchial asthma in this country.
Collapse
Affiliation(s)
- M E Soto-Quiros
- Department of Pediatrics, National Children's Hospital, University of Costa Rica, San José, Costa Rica
| | | | | | | | | | | |
Collapse
|
45
|
Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem 1997; 40:3456-65. [PMID: 9341921 DOI: 10.1021/jm9702084] [Citation(s) in RCA: 78] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
As a part of studies on structure-activity relationships, several potential topoisomerase I inhibitors were prepared. Different analogues of the antitumor antibiotic rebeccamycin substituted on the imide nitrogen with a methyl group were synthesized. These compounds bore either the sugar residue of rebeccamycin, with or without the chlorine atoms on the indole moieties, or modified sugar residues (galactopyranosyl, glucopyranosyl, or fucopyranosyl) linked to the aglycone via a beta- or alpha-N-glycosidic bond. Their inhibitory properties toward protein kinase C, topoisomerase I, and topoisomerase II were examined, and their DNA-binding properties were investigated. Their in vitro antitumor activities against murine B16 melanoma and P388 leukemia cells were determined. Their antimicrobial activities were tested against Gram-positive bacteria Bacillus cereus and Streptomyces chartreusis, Gram-negative bacterium Escherichia coli, and yeast Candida albicans. These compounds are inactive toward topoisomerase II but inhibit topoisomerase I. A substitution with a methyl group on the imide nitrogen led to a loss of proteine kinase C inhibition in the maleimide indolocarbazole series but did not prevent topoisomerase I inhibition. Compounds possessing a beta-N-glycosidic bond, which fully intercalated into DNA, were more efficient at inhibiting topoisomerase I than their analogues with an alpha-N-glycosidic bond; however, both were equally toxic toward P388 leukemia cells. Dechlorinated rebeccamycin possessing a methyl group on the imide nitrogen was about 10 times more efficient in terms of cytotoxicity and inhibition of topoisomerase I than the natural metabolite.
Collapse
Affiliation(s)
- F Anizon
- Synthèse, Electrosynthèse et Etude de Systèmes à Intérêt Biologique, Université Blaise Pascal, UMR 6504, Aubière, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Pereira ER, Belin L, Sancelme M, Prudhomme M, Ollier M, Rapp M, Sevère D, Riou JF, Fabbro D, Meyer T. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem 1996; 39:4471-7. [PMID: 8893841 DOI: 10.1021/jm9603779] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A series of compounds structurally related to staurosporine, rebeccamycin, and corresponding aglycones was synthesized, and their activities toward protein kinase C and topoisomerases I and II were tested together with their in vitro antitumor efficiency against murine B16 melanoma and P388 leukemia cells. Their antimicrobial activities were also examined against a Gram-negative bacterium (Escherichia coli), a yeast (Candida albicans), and three Gram-positive bacteria (Bacillus cereus, Streptomyces chartreusis, and Streptomyces griseus). To avoid side effects expected with protein kinase C inhibitors, we introduced substitution on the maleimide nitrogen and/or a sugar moiety linked to one of the indole nitrogens to obtain specific inhibitors of topoisomerase I with minimal activities on protein kinase C. As expected, these structures were inefficient on topoisomerase II, and some of them exhibited a strong activity against topoisomerase I. Generally, dechlorinated compounds were found to be more active than chlorinated analogues against both purified topoisomerase I and protein kinase C. On the other hand, opposite results were obtained in the cell antiproliferative assays. These results suggest lack of cell membrane permeability in the absence of the chlorine residue or cleavage of carbon-chlorine bonds inside the cell.
Collapse
Affiliation(s)
- E R Pereira
- Université Blaise Pascal, URA 485 du CNRS, Aubière, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
BACKGROUND A considerable fraction of newly constructed buildings have indoor air problems associated with health effects, usually of the nonspecific sick building syndrome variety. Specific health effects such as asthma, rhinitis, and allergic alveolitis can also occur. CASE On 1 September 1988 a school teacher showed symptoms of an acute respiratory illness, which was first interpreted as pulmonary embolism and then later as atypical sarcoidosis. The illness slowly progressed over six years, at which time the diagnosis was revised to chronic allergic alveolitis, related to her school environment. The school had had indoor-air quality problems off and on for several years. CONCLUSIONS The case illustrates the difficulties of diagnosing cases of chronic allergic alveolitis, especially when it appears in environments where it is not generally encountered. It also raises questions regarding a possible relation between environments associated with the sick building syndrome and the occurrence of building-associated illnesses.
Collapse
Affiliation(s)
- A Thörn
- Unit for Occupational Medicine, County Hospital, Boden, Sweden
| | | | | |
Collapse
|
48
|
Abstract
A survey was conducted at 15 textile plants with dyehouses in western Sweden. Employees with a history of work related rhinitis, asthma, or skin symptoms were offered a clinical and immunological investigation including skin prick tests, skin patch tests, and radioallergosorbent tests (RASTs) to detect specific allergy to reactive dyes. Among the 1142 employees, 162 were exposed to reactive dyes and 10 of these (6%) reported work related respiratory or nasal symptoms. An allergy to reactive dyes could be confirmed in five (3%, 95% confidence interval 1-7%). All but one had been exposed to reactive dyes for one year or less before the onset of symptoms. Positive RASTs could be detected in four of the five patients. All of the RAST positive patients were positive to remazol black B, but six out of eight additional remazol dyes also elicited positive results. RAST and RAST inhibition showed a cross reactivity between some of the dyes. Seven persons with work related dermatitis and three with urticaria or Quincke oedema were found. In one patient contact dermatitis to a monoazo dye was shown, but no positive patch test reactions to reactive dyes. IgE-mediated allergy to reactive dyes seems to be an important cause of respiratory and nasal symptoms among dyehouse employees exposed to dust from reactive dyes.
Collapse
Affiliation(s)
- R Nilsson
- Department of Occupational Medicine, Sahlgrenska Hospital, Göteborg, Sweden
| | | | | | | | | |
Collapse
|
49
|
Larsson K, Eklund A, Malmberg P, Belin L. Alterations in bronchoalveolar lavage fluid but not in lung function and bronchial responsiveness in swine confinement workers. Chest 1992; 101:767-74. [PMID: 1541145 DOI: 10.1378/chest.101.3.767] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Testing of lung function and bronchial reactivity, bronchoalveolar lavage (BAL), and a skin prick test with a standard panel and six "swine" extracts obtained from swine and swine environment were performed in 20 randomly selected nonsmoking swine confinement workers. In addition, blood samples for detection of antibodies by the diffusion in gel-enzyme-linked immunosorbent assay (DIG-ELISA) technique and precipitating antibodies were drawn. Air samples for measurement of dust and endotoxin levels were collected. All the farmers regarded themselves as healthy. The results were compared with reference groups consisting of urban nonsmoking subjects who had not been exposed to pig farming environment. The pig farmers had normal lung function and the bronchial reactivity was not different from the reference group. In the BAL fluid of the farmers, the concentration of total cells and granulocytes was increased while the concentrations of lymphocytes and macrophages were normal. The BAL fluid concentrations of albumin, fibronectin, and hyaluronan were elevated in the farmers. Skin prick tests with swine extracts were negative in all farmers. Antibodies (assessed by DIG-ELISA) against swine dander, swine dust, and pig feed were increased and precipitating antibodies against swine dander were found in 14, against pig food in five, and against swine confinement dust in three of the 20 pig farmers. The concentration of airborne total dust was 7.4 mg/cu mm and the endotoxin concentration was 37 (22 to 60) ng/cu mm during tending the pigs and increased, during feeding, to 13.8 mg/cu mm and 315 (194 to 716) ng/cu mm, respectively. There was no correlation between exposure and lung function or lavage findings. In conclusion, randomly selected pig farmers had signs of airway inflammatory reaction and activation of the immune system without alteration in lung function and bronchial reactivity.
Collapse
Affiliation(s)
- K Larsson
- National Institute of Occupational Health, Solna, Sweden
| | | | | | | |
Collapse
|
50
|
Larsson K, Eklund A, Malmberg P, Bjermer L, Lundgren R, Belin L. Hyaluronic acid (hyaluronan) in BAL fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis. Chest 1992; 101:109-14. [PMID: 1309495 DOI: 10.1378/chest.101.1.109] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Pulmonary function measurements, bronchoalveolar lavage (BAL), and analyses of precipitating antibodies in blood were performed in 12 farmers wtih no symptoms from the airways and 12 farmers who were admitted to the hospital due to acute symptoms of alveolitis (all nonsmokers). In addition, a bronchial methacholine provocation test was performed in the asymptomatic farmers. In 11 of the 12 symptomatic farmers but in none of the asymptomatic farmers, precipitating antibodies against one or more of the microorganisms which usually occur in a farmer's environment were found. In the farmers with symptomatic alveolitis, a restrictive impairment of pulmonary function was found, while pulmonary function was normal in all asymptomatic farmers. Findings in the BAL fluid showed increased concentrations of total cells, lymphocytes, and neutrophils and elevated levels of albumin, fibronectin, and angiotensin-converting enzyme in asymptomatic farmers compared with our own reference group. The same analyses in BAL fluid from the symptomatic farmers revealed a further increase in all parameters compared with the asymptomatic farmers. The BAL fluid from asymptomatic farmers had normal levels of hyaluronic acid (hyaluronan) and procollagen 3 N-terminal peptide, while these levels were significantly increased in the symptomatic group. We conclude that inflammation in the alveolar space and signs of activation of alveolar macrophages are present in farmers regardless of respiratory symptoms, although these findings are more pronounced in the presence of symptoms of acute alveolitis; however, the findings of impaired pulmonary function and the occurrence of precipitins and elevated levels of hyaluronic acid and procollagen 3 N-terminal peptide in BAL fluid were exclusively found in the farmers with airways symptoms. We postulate the hyaluronic acid, due to its pronounced ability to immobilize water, may be of importance in the development of the pulmonary function impairment observed in farmer's lung disease.
Collapse
Affiliation(s)
- K Larsson
- Respiratory Division, National Institute of Occupational Health, Solna, Sweden
| | | | | | | | | | | |
Collapse
|